Conference Preview: Avenacy Updates 2025 Strategy Ahead of J.P. Morgan Healthcare Event
Avenacy, a specialty pharmaceutical company focused on providing critical injectable medications, has shared updates regarding its recent business achievements, financial performance for 2024, and strategic priorities for 2025. This announcement comes ahead of Avenacy’s participation in the 43rd Annual J.P. Morgan Healthcare Conference, scheduled from January 13-16, 2025, in San Francisco, CA.
“2024 was a breakout year for Avenacy, marked by exceptional growth and tremendous progress. Through our industry-leading speed to market and steadfast commitment to quality, safety, and reliability, we have demonstrated our value as a clear partner of choice for hospitals and providers in need of essential medications,” said Jeff Yordon, Co-Founder & CEO of Avenacy. “2025 Conference will be a pivotal year for the organization, and we are confident in our ability to achieve our ambitious portfolio and broader business goals. As we continue to position our business for accelerated growth, we remain committed to our mission of enhancing patient care and addressing critical gaps in the U.S. healthcare system.”
2024 and Recent Business Highlights
Avenacy’s solid performance in 2024 Conference has laid a strong foundation for future growth. The company’s first full year of operation showed its capability to deliver results. Avenacy’s revenue was primarily driven by its foundational portfolio, which includes 14 critical injectable medicines. The company expects this portfolio to generate robust annual sales growth and gross profit expansion in the years ahead.
To support continued scale-up and rapid growth, Avenacy focused on building out its commercial leadership and infrastructure. This includes forming wholesaler agreements with industry leaders such as Cardinal, McKesson, ABC/Cencora, Morris Dickson, as well as smaller specialty wholesalers. The company also completed its sales team hiring across major U.S. geographies and secured the necessary state licenses to operate effectively.
Additionally, Avenacy strengthened its leadership and financial position by adding Dr. Patrick Soon-Shiong to its Board and co-founding team. With over 25 years of pharmaceutical industry experience, including successful commercialization of injectable generic drugs, Dr. Soon-Shiong brings invaluable expertise to Avenacy.
Avenacy’s commitment to product differentiation is evident in the company’s packaging and labeling efforts, which assist pharmacists and clinicians in accurate medication selection. The company continues to pursue opportunities to improve the safety and convenience of its products, including ready-to-use dosage forms, formulations that are easier to store, and extended expiration dating. In line with its mission to fill gaps in the healthcare system, Avenacy is monitoring current drug shortages and exploring strategic opportunities to address them.
2025 Strategic Priorities
Avenacy’s strategic focus for 2025 is ambitious. The company aims to launch 25 or more products by the end of the year. Avenacy has a robust pipeline of signed products targeted for launch in the next two years, including several products with market sizes exceeding $100M.
Building on its foundational portfolio, Avenacy will continue to focus on critical acute care medications and shortage products, which have higher adoption rates in the hospital market. The company views this as a near-term opportunity to establish its market presence quickly while maintaining a cost-effective business model.
Avenacy is also seeking to secure additional investment to support its long-term growth portfolio, which will include products with higher anticipated returns, such as market formation products and those filed under Avenacy-owned Abbreviated New Drug Applications (ANDAs). The company expects that this investment will help solidify its position as a leading provider of generic injectable medications.
Avenacy’s successful capital raise in August 2024 enabled the company to secure products for launch in 2025, contributing to its expected financial growth. The company is now seeking additional funding to expand both its foundational and growth portfolios and invest in more revenue-generating assets.
“As Avenacy enters its second year of operations, we are excited about the progress we’ve made and the opportunities ahead. We will continue to seek capital funding to support strategic portfolio development and ensure long-term growth,” said Joe Mase, Chief Operating Officer at Avenacy.
Participation at 43rd Annual J.P. Morgan Healthcare Conference
Avenacy’s executive team, including Jeff Yordon, Co-Founder & CEO, Joe Mase, Chief Operating Officer, and Peter Jensen, Vice President of Finance, will attend the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. At the conference, Avenacy will meet with investors to showcase its recent accomplishments and discuss its strategic plans for 2025. This conference will provide a platform for the company to engage with stakeholders and provide insights into its growth trajectory and future ambitions.
About Avenacy
Avenacy is a U.S.-based specialty pharmaceutical company dedicated to supplying critical injectable medications used in medically supervised settings, such as acute care hospitals, outpatient clinics, and physician offices. The company is actively building a pipeline of high-quality, FDA-approved injectable products to meet the needs of today’s dynamic drug supply chain.
Avenacy is committed to quality, reliability, and safety, striving to be a trusted partner for essential medications while ensuring efficient patient care. With an experienced team and an innovative approach, Avenacy is positioning itself as a leader in the injectable pharmaceutical market. The 43rd Annual J.P. Morgan Healthcare Conference will be a key event for the company to outline its continued commitment to these goals and its strategic priorities for the future.
Please find the related post
